Arca
Skip to content
Tools
Tools

Migraine

Drug research and approvals for migraine: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 175 studies of migraine are recruiting on ClinicalTrials.gov, Health Canada has authorized 50 drug trials for it since 2013, FDA has 0 approved and 2 open orphan designations naming it, and the EU has 7 authorised medicines for it.

  • Recruiting worldwide: 175
  • Trials authorized in Canada: 50
  • FDA orphan approvals: 0
  • EU medicines: 7

Recruiting now

Newest posted first, of 175 recruiting on ClinicalTrials.gov ↗

How its trials ended

1,356 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 388 whose ending is known, 60% met their primary endpoint, 7% missed it and 32% stopped early.

  • Completed, result not reported55741%
  • Ongoing26520%
  • Met its primary endpoint23417%
  • Status unknown14611%
  • Stopped: other or unclear725%
  • Stopped: enrollment or feasibility302%
  • Missed its primary endpoint282%
  • Stopped: lack of efficacy111%
  • Stopped: sponsor or business decision91%
  • Stopped: funding3<1%
  • Stopped: safety1<1%

Trials authorized in Canada

The 10 newest of 50; search them all in Canada trials
Aug 10, 2026A randomized, double-blind, placebo controlled study evaluating the efficacy and safety of EVO756 for the prevention of migraine in adultsEVO756EvommuneOngoing
Jul 2, 2026Eptinezumab for the acute treatment of status migrainosus in the emergency department of a community hospital (ed-relief)VyeptiSanté Québec- Centre Hospitalier De L’université De MontréalPending
Sep 10, 2025A multicentre, randomised, double-blind, placebo-controlled, dose escalation and dose finding phase II study to evaluate the safety and efficacy of IPN10200 in…IPN10200IpsenOngoing
Aug 14, 2025Cannabis for the prophylactic treatment of migraine: a randomized double-blind placebo-controlled clinical trialCB-81 (cannabidiol-DELTA-9-tetrahydrocannabinol)Governors of The University of CalgaryOngoing
Jul 16, 2025A phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial with extension period to evaluate the efficacy and safety of xeomin®…XeominMerz Therapeutics GmbHOngoing
Jul 16, 2025A phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial with extension period to evaluate the efficacy and safety of xeomin®…XeominMerz Therapeutics GmbHOngoing
Mar 26, 2025An interventional efficacy and safety, phase 3, double-blind, parallel-group study to investigate intermittent prevention of menstrual migraine with rimegepant…Rimegepant (PF-07899801)PfizerOngoing
Mar 6, 2025A phase 3, multicenter, 12-week, double blind, placebo-controlled study to evaluate the safety and efficacy of atogepant for the preventive treatment of…AtogepantAbbVieOngoing
Jul 23, 2024Eptinezumab as an adjunct to standard of care for migrane in an acute emergency context (migraine erase study)VyeptiFraser Health AuthorityOngoing
Oct 5, 2023An interventional, efficacy and safety, phase 3, double-blind, 3-arm, study to investigate pain response with intranasal (IN) zavegepant compared with placebo…Zavegepant (PF-07930207)PfizerClosed

FDA orphan designations

Approved first, then open designations, newest first
Mar 25, 2026(S)-N-(4-(2-(4-chlorophenyl)but-3-yn-2-yl)…Treatment of retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and migraine headache (ROSAH) syndromeDrug FarmDesignated
Jul 20, 2016FlunarizineTreatment of hemiplegic migraineXenon Pharmaceuticals, Inc.Designated

Medicines authorised in the EU

Newest first
Aug 11, 2023AquiptaAtogepantAbbVie Deutschland GmbH & Co. KGEMA ↗
Aug 17, 2022RayvowLasmiditanEli Lilly Nederland B.V.EMA ↗
Apr 25, 2022VyduraRimegepantPfizer Europe MA EEIGEMA ↗
Jan 24, 2022VyeptiEptinezumabH. Lundbeck A/SEMA ↗
Mar 28, 2019AjovyFremanezumabTeva GmbHEMA ↗
Nov 14, 2018EmgalityGalcanezumabEli Lilly Nederland B.V.EMA ↗
Jul 26, 2018AimovigErenumabNovartis Europharm LimitedEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.